|Bid||0.00 x 1800|
|Ask||0.00 x 800|
|Day's Range||18.48 - 19.02|
|52 Week Range||11.00 - 22.82|
|Beta (3Y Monthly)||2.08|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -12.50% and 121.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
The immune cells live up to their name in natural settings, but engineered therapies have delivered mixed results in clinical trials.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
If you're interested in Fate Therapeutics, Inc. (NASDAQ:FATE), then you might want to consider its beta (a measure of...
Fate Therapeutics (FATE) delivered earnings and revenue surprises of -30.43% and -10.54%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 30 cents. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
Does Fate Therapeutics Inc (NASDAQ:FATE) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend […]
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Fate Therapeutics, Inc.'s (NASDAQ:FATE) latest earnings update in December 2018Read More...
Investors will focus on regular top and bottom-line numbers along with pipeline progress when Cronos (CRON) reports fourth-quarter results.
Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J. Wolchko became the CEO of Fate Therapeutics, Inc. (NASDAQ:FATE) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider Read More...
On December 21, Vanda Pharmaceuticals (VNDA) stock closed at $24.00, which is a ~1.64% decline from its prior close of $24.40 on December 20, 2018. Vanda Pharmaceuticals stock price grew from $15.20 at the close of market on December 29, 2017, to $24.00 on December 21, 2018, reflecting ~58% YTD growth.
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]